Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · IEX Real-Time Price · USD
6.96
-0.24 (-3.33%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ATNM stock have an average target of 25.6, with a low estimate of 11.6 and a high estimate of 50. The average target predicts an increase of 267.82% from the current stock price of 6.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ATNM stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 1 | 2 | 2 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +618.39% | Jun 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +618.39% | May 21, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $25 | Buy | Initiates | $25 | +259.20% | May 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +618.39% | May 2, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $21 | Buy | Reiterates | $21 | +201.72% | Apr 30, 2024 |
Financial Forecast
Revenue This Year
193.12K
from 81.00K
Increased by 138.42%
Revenue Next Year
58.17M
from 193.12K
Increased by 30,021.18%
EPS This Year
-1.57
from -1.83
EPS Next Year
-0.45
from -1.57
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.2M | 148.4M | 351.2M | 625.1M | 852.7M |
| Avg | 193,117 | 58.2M | 139.0M | 243.9M | 376.9M |
| Low | n/a | 18.0M | 69.0M | 127.3M | 187.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1,372.8% | 76,729.2% | 503.8% | 349.8% | 249.7% |
| Avg | 138.4% | 30,021.2% | 138.9% | 75.5% | 54.6% |
| Low | - | 9,226.0% | 18.7% | -8.4% | -23.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.39 | 1.33 | 4.45 | 8.34 | 11.29 |
| Avg | -1.57 | -0.45 | 1.10 | 2.44 | 4.37 |
| Low | -1.78 | -2.02 | -1.33 | -0.41 | 0.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 656.8% | 362.1% |
| Avg | - | - | - | 121.8% | 79.0% |
| Low | - | - | - | - | -71.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.